Health Care • Biotechnology: Pharmaceutical Preparations
$9.54 ▲ +0.00
(0.00%)
MKT CAP: $127.4M • VOL: 748
52W L $6 52W H $302
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
BGM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $37.9M | $25.1M | $46.5M |
| YoY Revenue Growth % | +51.1% | -46.0% | — |
| Gross Profit | $6.3M | $4.1M | — |
| Gross Margin % | 16.6% | 16.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.6M | -$563.8K | -$2.6M |
| Operating Margin % | -33.2% | -2.2% | -5.6% |
| Net Income (GAAP) | -$19.9M | -$1.4M | -$7.8M |
| EBITDA (Normalized) | -$11.3M | -$371.7K | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.4M | $544.2K | $312.2K |
| Capital Expenditures (CapEx) | $1.6M | $240.1K | — |
| Free Cash Flow (FCF) | -$3.9M | $304.1K | $312.2K |
| FCF Margin % | -10.4% | 1.2% | 0.7% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BGM.